Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

	News, Updates and Commentary
	News RSS Feed

Free Newsletter

We value your privacy. We will not rent your email to anyone.

Extended Drug Therapy for Hepatitis Is Challenged
Patients who do not initially respond to standard drug therapy for treatment of hepatitis C are unlikely to respond to long-term maintenance therapy as well, according to a new study. Yet many patients who do not at first respond to drugs are placed on

Gilead Sciences, Inc. (GILD) Release: Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
FOSTER CITY, Calif.--(BUSINESS WIRE)-- (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread (tenofovir disoproxil fumarate) for the

Interferon as long-term treatment for hepatitis C not effective
Results of the 3-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today's issue of . The researchers found no difference in the rate of progression of liver disease among patients who received

UPDATES AND COMMENTARY

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

Safety and Immunogenicity of
Hepatitis A Vaccine in Patients With Chronic Liver Disease

table 2. Adverse Events Related/Possibly Related to Vaccination with Hepatitis A and B Vaccines in Healthy Subjects and Persons With CLD

	Hepatitis A Vaccine				HAV vs. HBV Vaccine
	Hepatitis A Vaccine				Hepatitis C
	Healthy (n = 371)	Hepatitis B (n = 91)	Hepatitis C (n = 200)	Others^* (n = 136)	(n = 200)	(n = 197)

Local symptoms	37.2%	44%	37.5%	44.9%	37.5%	19.8%
		(P = .279)	(P = 1.000)	(P = .125)	(P = .0001)
General symptoms	11.1%	16.5%	24.5%	27.9%	24.5%	19.3%
		(P = .007)	(P < .0001)	(P < .0001)	(P = .207)

NOTE. The incidence of local and general symptoms in each of the cohorts of CLD subjects was compared separately with that in healthy subjects by Fisher's Exact test. Abbreviation: HBV, hepatitis B virus. ^* Others = chronic liver disease of etiology other than hepatitis B or C.

Return To Article

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008